72726-63-7 Usage
Uses
Used in Pharmaceutical Industry:
4-Hydroxymethyl-nicotinic acid is used as a therapeutic agent for its potential role in managing various health conditions. Its anti-inflammatory and antioxidant properties make it a candidate for treating inflammation-related disorders and oxidative stress-associated conditions.
Used in Diabetes Management:
In the healthcare industry, 4-HMNA is utilized as a potential treatment for diabetes due to its capacity to influence metabolic pathways and improve insulin sensitivity, thereby helping in the management of blood sugar levels.
Used in Cardiovascular Disease Treatment:
4-Hydroxymethyl-nicotinic acid is employed as a component in cardiovascular therapies, leveraging its potential to impact lipid metabolism and reduce the risk of atherosclerosis, thereby contributing to the prevention and treatment of cardiovascular diseases.
Used in Neurodegenerative Disorder Research:
In the field of neuroscience and neurology, 4-HMNA is used as a subject of research for its potential to mitigate the effects of neurodegenerative disorders. Its involvement in cellular metabolism and energy production makes it a promising candidate for further exploration in this area.
Check Digit Verification of cas no
The CAS Registry Mumber 72726-63-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,7,2 and 6 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 72726-63:
(7*7)+(6*2)+(5*7)+(4*2)+(3*6)+(2*6)+(1*3)=137
137 % 10 = 7
So 72726-63-7 is a valid CAS Registry Number.
72726-63-7Relevant academic research and scientific papers
Comparison of Azabicyclic Esters and Oxadiazoles as Ligands for the Muscarinic Receptor
Orlek, Barry S.,Blaney, Frank E.,Brown, Frank,Clark, Michael S. G.,Hadley, Michael S.,et al.
, p. 2726 - 2735 (2007/10/02)
The link between the cognitive deficit associated with Alzheimer type dementia and the loss of cholinergic function in the disease provides a basis for examining muscarinic agonists as potential therapeutic agents.This paper describes the design and synthesis of novel azabicyclic methyl esters as ligands for the muscarinic receptor.Replacement of the methyl ester by a 3-methyl-1,2,4-oxadiazole ring produces potent metabolically more stable muscarinic agonists capable of penetrating the central nervous system.These compounds generally show improved affinity relativeto the corresponding methyl esters. 3-Methyl-1,2,4-oxadiazole 7b has an affinity 4 times that of acetylcholine.Receptor affinity is discussed in relation to the size and geometry of the azabicyclic ring and the electronic properties of the heteroaromatic ring.
